IP Library Granted Patent US 11,866,741
Granted Patent B2
US 11,866,741 · App. 17/350,078 · Granted Jan 9, 2024

Polymerase enzyme from 9°N

Inventors: Jerzy Olejnik (Brookline, MA); Angela Delucia (Cambridge, MA)
Assignee: IsoPlexis Corporation
C12N9/1252C12Q1/6844C12Q1/6869C12Y207/07007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,866,741
App. No.
17/350,078
Granted
Jan 9, 2024
Kind
B2
Abstract

The present invention relates to a polymerase enzyme from 9° N with improved ability to incorporate reversibly terminating nucleotides. The enzyme comprising mutations in the motif A region. The invention also relates to methods of using such enzymes as well as a kit with such polymerases.

Claims (17)

1. A polymerase enzyme that shares at least 95% amino acid sequence identity to SEQ ID NO:1, comprising the following mutation(s): L408S, Y409G, and P410S, and

wherein the polymerase enzyme has little or no 3′-5′ exonuclease activity.

2. The polymerase according to claim 1 , wherein the polymerase is from an organism belonging to the genera of Pyrococcus.

3. The polymerase according to claim 1 , wherein the polymerase additionally, comprises one or more of the following additional mutations D141A, E143A.

4. The polymerase according to claim 1 , wherein the polymerase additionally comprises the mutation A485L.

5. The polymerase according to claim 1 , wherein the enzyme shares 98% sequence identity with SEQ ID NO: 1 and additionally has the following set of mutations, (i) L408S, Y409G, P410S and (ii) A485L.

6. The polymerase according to claim 1 , wherein the enzyme has an amino acid sequence according to SEQ ID NO: 2 or SEQ ID NO: 3.

7. The polymerase according to claim 1 , which exhibits an increased rate of incorporation of nucleotides which have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group compared to the control polymerase.

8. A nucleic acid molecule encoding a polymerase according to claim 1 .

9. An expression vector comprising the nucleic acid molecule of claim 8 .

10. A method for incorporating nucleotides which have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group into DNA, the method comprising:

a) providing a reaction mixture comprising the following substances (i) a polymerase according to claim 1 , (ii) template DNA, (iii) one or more nucleotides, which have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group, and

b) subjecting said reaction mixture to conditions which enable the polymerase to catalyze the primer extension reaction.

11. Use of a polymerase according to claim 1 for DNA sequencing, DNA labeling, primer extension, or nucleic acid amplification, comprising:

a) providing a reaction mixture comprising the following substances (i) a polymerase according to claim 1 , (ii) template DNA, and (iii) one or more nucleotides, which have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group, and

b) subjecting said reaction mixture to conditions which enable the polymerase to incorporate one or more nucleotides to the template DNA.

12. A kit comprising a polymerase according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: OLEJNIK, JERZY; DELUCIA, ANGELA
To: QIAGEN WALTHAM, INC.
Reel/Frame 057086/0049 →
MERGER Recorded Aug 5, 2021
From: QIAGEN WALTHAM, INC.
To: QIAGEN SCIENCES, LLC
Reel/Frame 057086/0059 →
PATENT PURCHASE AGREEMENT Recorded Aug 5, 2021
From: QIAGEN SCIENCES, LLC
To: ISOPLEXIS CORPORATION
Reel/Frame 057088/0979 →
Priority Claims (1)
EP 17160392 · Mar 10, 2017 · regional
Continuity (3)
Continuation 16485279
Provisional Application 62458404 · Feb 13, 2017
Related Publication 20210317423A1 · Oct 14, 2021